Navigation Links
Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases
Date:11/2/2009

he first systemically administered siRNA, as well as additional pre-clinical stage compounds, through important value-enhancing milestones in 2010. We look forward to presenting these case studies reflecting the success of our proprietary programs."

QPI-1002 targets p53, a stress-response gene that plays a pivotal role in the apoptotic pathway. Temporary inhibition of p53 at the time of injury delays cell death, allowing natural repair mechanisms to restore normal DNA and cellular integrity. QPI-1002 is currently being evaluated in a Phase I/IIa clinical study for the prevention of acute kidney injury (AKI) and in Part A of a Phase I/II clinical study for the prophylaxis of delayed graft function (DGF) following renal transplantation. Both studies are scheduled to be completed this year.

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company engaged in discovering and developing novel RNAi-based therapeutics. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability for non-invasive delivery of siRNA to target tissues and organs including the eye, ear, lung, spinal cord and brain.

Quark's clinical pipeline includes PF-4523655 (RTP801i-14), currently in Phase II clinical trials for Diabetic Macular Edema (DME) and Age-related Macular Degeneration (AMD). PF-4523655 is a synthetic, chemically modified siRNA designed to inhibit the expression of the gene RTP801 discovered by Quark through the gene discovery platform BiFAR. PF-4523655 is licensed to Pfizer. In addition, Quark's current clinical pipeline includes QPI-1002, the first systemically administered siRNA drug in human clinical trials, developed by Quark for the prevention of acu
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
2. Quark Pharmaceuticals Presents at Asia TIDES Conference
3. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
4. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
5. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
6. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
9. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
10. Quark Pharmaceuticals Appoints New Chief Medical Officer
11. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... --  Gulf Coast Tattoo Removal is the first and only ... laser in Southern Mississippi . Gulf Coast Tattoo ... take back control of their skin. The clinic is located in ... Biloxi , Gulfport , and ... as prevalent as it is, I was surprised by the lack ...
(Date:9/2/2015)... 2, 2015 Research and Markets ( ... "An Introduction to Medical Device Software: Regulations ... conference to their offering. ... the regulations and requirements that apply to Medical ... using real life examples and state-of- the-art practices ...
(Date:9/2/2015)... 2015  Research and Markets ( http://www.researchandmarkets.com/research/rf2c5p/an_introduction ) ... Introduction to the Medical Devices Directive (London, UK ... offering. This seminar provides a ... It will explain the Directives and which products ... to choose one and outline what a manufacturer ...
Breaking Medicine Technology:Gulf Coast Tattoo Removal Delivers Unrivaled Tattoo Removal Results To Biloxi And Gulfport With Astanza Duality 2An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2
... Reportlinker.com announces that a new market research ... Strategic Analysis of End-user Preferences in the ... http://www.reportlinker.com/p0258289/Strategic-Analysis-of-End-user-Preferences-in-the-US-Stem-Cell-Research-Tools-Markets.html The primary ... perceptions of tools and technologies currently at the ...
... Safety and Clinical Benefits of Radioactive Microspheres in... -- ROME, August 19, 2010 ... ... --> ... = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Medicine Technology:Reportlinker Adds Strategic Analysis of End-user Preferences in the U.S. Stem Cell Research Tools Markets 2Reportlinker Adds Strategic Analysis of End-user Preferences in the U.S. Stem Cell Research Tools Markets 3Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 2Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 3Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 4Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 5Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 6Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 7Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 8Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 9
(Date:9/2/2015)... ... 2015 , ... Good health and a good cause paired up at The ... BCBSNJ) donated $11,000 to the New Jersey Golf Foundation through its Healthy Steps Challenge. ... The Barclays, Horizon BCBSNJ challenged PGA TOUR golfer and NJ native Morgan Hoffmann to ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... of 200 food banks in commemorating “Hunger Action Month” during the entire month ... mobilization, the Food Bank will be dedicating its efforts this September to an ...
(Date:9/2/2015)... ... 2015 , ... Ericson is a noted speaker and educator in the field ... of Education for the Association for Clinical Documentation Improvement Specialists (ACDIS) where she developed ... She serves as a CDI subject matter expert for a variety of HCPro and ...
(Date:9/2/2015)... MN (PRWEB) , ... September 02, 2015 , ... Every ... to it; others dread it. However, few are prepared to face the academic workload ... school starts. Our schools haven’t prepared them since schools don’t teach students how to ...
(Date:9/2/2015)... , ... September 02, 2015 , ... Amada Senior Care, ... office in Kansas – its Johnson County location. Amada franchise partners Mike ... has a registered nurse background and spent over 20 years in medical device sales ...
Breaking Medicine News(10 mins):Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 2Health News:Horizon BCBSNJ’s Healthy Steps Challenge Raises an Additional $6,000 for the NJ Golf Foundation with Help from PGA TOUR Golfer Morgan Hoffmann 3Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 2Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 3Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 4Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 3Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 4Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 2Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 3Health News:Amada Senior Care Expands to Greater Kansas City 2
... of Americans want no changes to the health care legislation ... may be more common ground with other Americans than many ... Indiana University,s Center for Health Policy and Professionalism Research (CHPPR). ... the new law:, 21 percent said they were completely ...
... heart-related conditions, researchers say , SATURDAY, April 24 ... with noncardiac (not heart-related) chest pain may require ... receive, a new study has found. , Noncardiac ... of problems, including panic attack, musculoskeletal pain, gastroesophageal ...
... ZSL, a ... new Business Power Cloud & Mobile Add-on Suite for Microsoft Dynamics CRM and ERP applications – ... ... a leading ISV and Microsoft Gold Certified Partner based out of Edison, New Jersey, today launched ...
... ... to existing training programs, and group portal access for clinical research studies., , ... Dallas, TX (PRWEB) April ... of CORE (TM) ( http://core.medtrials.com ). CORE (TM) stands for Clinical research Online ...
... ... celebrates 25th anniversary as leading off-utility industrial power supplier , ... Tulsa, OK (PRWEB) April 24, 2010 -- ... as a financially secure American company by opening our 7th industrial power location in ...
... , ... All My Children star for her work on behalf of Parkinson,s research ... East Islip, NY (PRWEB) April 24, 2010 ... philanthropist, a corporation and a person afflicted by the disease who have come together to find ...
Cached Medicine News:Health News:More common ground in health care reform law disagreement than meets the eye 2Health News:Noncardiac Chest Pain May Warrant More Management: Study 2Health News:ZSL Launches Cloud & Mobile Add-on Suites for Microsoft Dynamics ERP and CRM Applications 2Health News:ZSL Launches Cloud & Mobile Add-on Suites for Microsoft Dynamics ERP and CRM Applications 3Health News:MedTrials Launches New Online Training Website: http://core.medtrials.com 2Health News:Emmy-Award Winning Actress Susan Lucci to Receive Philanthropic Leadership Award at 7th Annual Cure for Sure Dinner 2Health News:Emmy-Award Winning Actress Susan Lucci to Receive Philanthropic Leadership Award at 7th Annual Cure for Sure Dinner 3
... The Featured Products ... at Mediflex and are ... modular in regular or ... come equipped with insulation, ...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
Medicine Products: